- Review the latest evidence-based guidelines on implementing complication-centric treatment options in persons living with type 2 diabetes.
- Identify methods to intensify therapies to reach timely, sustained glycemic targets and maintain weight or promote weight loss.
- Apply shared decision-making strategies with sustained glycemic targets and personalized weight management as key goals in persons living with T2D to prevent long-term health implications.
Madhuri Vasudevan, MD, MPH
Assistant Professor
Endocrinology, Diabetes and Metabolism
Baylor College of Medicine
Radica Alicic, MD, FHM, FACP
Associate Director of Research, Inland Northwest Washington
Clinical Professor of Medicine UW School of Medicine
Providence Medical Research Center
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP
Endocrine Clinical Pharmacy Specialist
CGM Program Coordinator
Co-Director Center of Excellence for Endocrine Disorders in Pregnancy
Cleveland Clinic Endocrinology & Metabolism Institute
The American College of Endocrinology (ACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American College of Endocrinology (ACE) designates this enduring activity for a maximum of 3.5 AMA PRA Category 1TM Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Only those who receive a passing score will be eligible for MOC credit.
Nurses
American Association of Clinical Endocrinology is approved by the California Board of Registered Nursing, Provider Number 17762, for 3.5 contact hours.
All of the relevant financial relationships listed for these individuals have been mitigated. All other planners for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All of the relevant financial relationships listed for these individuals have been mitigated.
Planners
- Diane Alberson, MEd, CAE - No relationships to disclose
- Amy Ogunsunlade - No relationships to disclose
- Audrey Shively, MSHSE, MCHES, CHPD - No relationships to disclose
- Madhuri Vasudevan, MD, MPH - No relationships to disclose
- Radica Alicic, MD, FHM, FACP - Bayer, research funding, advisory board member; Boehringer Ingelheim, consultant; Eli Lilly, consultant
- Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP - Abbott, Speakers’ Bureau; Dexcom, Speakers’ Bureau; Medtronic, Speakers’ Bureau, Consultant; Insulet, Speakers’ Bureau; Eli Lilly, Speaker’s Bureau, Consultant; Novo Nordisk, Speakers’ Bureau; Cequr, Speakers’ Bureau; Sanofi, Consultant; Lifescan, Consultant
Faculty
- Madhuri Vasudevan, MD, MPH - No relationships to disclose
- Radica Alicic, MD, FHM, FACP - Bayer, research funding, advisory board member; Boehringer Ingelheim, consultant; Eli Lilly, consultant
- Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP - Abbott, Speakers’ Bureau; Dexcom, Speakers’ Bureau; Medtronic, Speakers’ Bureau, Consultant; Insulet, Speakers’ Bureau; Eli Lilly, Speaker’s Bureau, Consultant; Novo Nordisk, Speakers’ Bureau; Cequr, Speakers’ Bureau; Sanofi, Consultant; Lifescan, Consultant
This activity is supported by independent educational grants from Abbott Diabetes Care, Dexcom, Inc., Medtronic, Inc., Novo Nordisk, and Lilly USA, LLC.